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Abstract
Uterine fibroids have remarkably heterogeneous clinical characteristics with 
unknown exact etiology. The treatment of fibroids should be individualized based 
on their size, location, growth rate, the symptoms that they cause, the desire 
to have children and the age of the woman. Embolization is currently the most 
advanced non-surgical technique. The majority of women report satisfactory 
post-treatment results like shorter hospitalization period and recovery time in 
comparison to hysterectomy and improvement or complete remission of clinical 
symptoms. Complications include amenorrhea (in the majority of cases: recur-
rence after three months) and infections that are generally treated with antibiotics. 
The results from most clinical studies and our published experience indicate that 
embolization improves pelvic symptoms related to uterine fibroids. Collaborative 
efforts between gynecologists and interventional radiologists are necessary in 
order to optimize the safety and efficacy of this procedure. In the future, emboli-
zation could be generally recommended as treatment option for women who desire 
future fertility/pregnancy.
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1. Introduction
Uterine fibroids are high prevalent benign tumors that originate from muscle 
cells of the uterus with remained incompletely understood incidence, progression 
disease and natural history [1]. The above mentioned tumors may appear single or 
multiple but usually remain asymptomatic [1, 2]. Fibroids appear in various areas 
of uterus, different sizes and exist not a general accepted classification system for 
fibroid evaluation [3, 4]. They represent a tremendous public health problem with 
multiple difficulties and financial cost on society [1–4].
Treatment strategies to prevent the fibroid limit growth and non-surgical treat-
ment are needed [5–8]. Minimally invasive methods like uterine artery embolization 
(UAE) as treatment option of fibroids by retaining the uterus among the women dur-
ing middle or late reproductive years is the summarized goal of this literature review 
with detailed 12 years results report of Department Obstetrics and Gynecology 
in cooperation with Interventional Radiology Unit of Radiology Department, 
Democritus University of Thrace in Greece. The aim of this retrospective study was 
to investigate the contribution of UAE and the occurrence of transient, or permanent 
amenorrhea as well as reappearance of regular menstruation, inflammation, pain in 
premenopausal women up to one year of postoperative follow-up UAE.
2. Incidence
The fibroids occur in a phenotype in wide of genetic diseases, clinically not as 
single disease entity and their progression varies and based on the various types 
of disease in different national groups [9, 10]. The incidence of asymptomatic but 
sonographically fibroids detected as remarkably high and the incidence depending 
on women age and race. Their prevalence is 9% in white women, three to nine times 
higher prevalence in African American, diagnosed in 3.3% of 25 to 32 year olds, 7.8% 
of the 33 to 40 year olds and increased 20-fold to 6.20 per 1000 women years by ages 
45to 50 [9–14]. Familial aggregation studies confirm heritability of fibroids 2.5 times 
more at risk in first degree relatives, increasing to 5.7 for women with an affected 
first degree relative of less than 45 years old. The grow and recur rate of fibroids after 
abdominal myomectomy reported as 5 year risk 62% with 9% risk an additional 
major surgical procedure. Relapses of 27% over a period of 10 years are reported 
with increasing frequency rate approaching to premenopausal period [9, 14, 15].
The recurrence risk is lower in women with single fibroid with small size and in 
those women who noticed a subsequent successful pregnancy. Oral contraceptives 
administration decreased the occurrence of fibroids depending to the duration of 
oral contraceptives use [16–18]. Moreover, early menarche and high body mass 
index (approximately 18% for each 19 kg increase) are some other factors that 
lead to the development of fibroids [9, 14, 15, 19]. Clinically fibroids occur at least 
three distinct phenotypes like: single, multiple varying size and in association with 
adenomyosis or alone [9]. Fibroids interfere not only with implantation but also 
with successful labor and if there are not existing, is for a woman more likely to be 
pregnant. Pregnancy prevents the development of fibroids, because is associated 
with fibroid inflated effect [9, 14, 16–18]. The risk of fibroids decrease with parity 
up to fivefold [9, 14]. Although subfertility may be caused by fibroids, however the 
detected fibroids during pregnancy not influence the age of delivery of the first 
child, but change the age of last term labor. The presence of fibroids in the major-
ity are not associated to any symptoms but is poorly explain their contribution to 
symptoms menstrual disorders heavy menstrual flow or longer duration of menses, 
pelvic pain and infertility. Based on the published literature is demonstrated a 
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relationship between diastolic pressure and fibroids [9, 16–20]. High diastolic blood 
pressures led to atherogenesis, cause injury and damage of muscle cells like a similar 
mechanism as in vascular muscle system, release cytokine in uterus muscle, which 
led to promotion of fibroid growth [9, 16–20]. Approximately 10 mm Hg increas-
ing of blood pressure led to 8–10% increased fibroid risk. Myometrial injury based 
either on ischemia, hypertension or atheromatic type mechanisms are associated 
positively also to pelvic inflammatory disease [9, 16–20]. The risk of fibroids is low, 
if the estrogen levels are low and this could be explain the low risk associated with 
smoking, alcohol and caffeine consumption.
3. Heritable disease associated to fibroids
Some fibroids reflected genetic syndromes feature fibroids development such 
Reed’s, Bannayan Zonana, Cowden syndrome, herediatary leiomatosis and renal 
cell cancer (HLRCC). Reed’s syndrome is well known as familial leiomyomatosis 
cutis and uteri (MIM150800) is an autosomal dominant trait with reduced pen-
etrance associated with cutaneous fibroids. Bannayan Zonana (MIM153480), 
Cowden (MIM158350) syndromes are autosomal dominant hamartomatous pol-
yposis disorders included lipomas, interstinal hamartomatous polyps and various 
nonneoplastic manifestations [21–24].
Intracellular mutation such as chromosomal translocations and deletions are 
reported. None of the mentioned patterns of inheritance have been clearly proved 
in fibroids as a solitary phenotype.
In addition, different genetic subtypes can be found in different fibroids of the 
same patient. Many fibroids in a uterus may be of different cytological origin. The 
heterogeneity from growth and development of fibroids based on enzyme glucose-
6-phosphate dehydrogenase (G6PD) isoenzyme analysis and using androgen recep-
tor (AR) gene assays reveal that fibroids are monoclonal lesions arise independently 
from the same uterus and may associated to various chromosomal abnormalities 
which results in a distinct fibroid is a monocyte in the origin of the monoclonal 
independent lesion [25–28].
In uterus referred high rate of estrogen receptors, which comprised spiral linear 
muscle fibers separated from the natural surrounding uterine muscle tissue by a 
pseudocapsule of connective tissue.. Many distinct factors contribute to tumor 
progression [25–28].
Approximately 40% of fibroids are karyotypically abnormal which compared to 
normal fibroids are generally more cellular and have a greater mitotic index lower 
DNA content. The most prevalent types of chromosomal aberrations are as fol-
lowing: t(12,14), (q14-q15,q23-q24), rearrangement of 6p21, del(7)(q22q32), 1p36, 
10q22, 13q21–22 nad of x chromosome partial deletion 3q, trisomy 12. [29–32]. 
Fibroids with abnormal karyotypes are associated to anatomically positions 12% of 
submucosal, 29% of subserosal and 35% of intramural. Based on low frequency of 
karyotypic rearrangement is the explanation that submucosal fibroids are highly 
symptomatic and led to menorrhagia. Further research in the genetics of fibroids is 
needed to investigate the heritability based on their clonal mosaic nature to corre-
late genotypic and clinically characteristics. [29–34].
4. Adenomyosis
In UAE practice for therapy of symptomatic types adenomyosis either of pure 
(diffuse, focal) or mix form (coexistence with fibroids) in 70% and 30% of cases 
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respectively depending on size and number of fibroids (adenomyosis dominance, 
fibroid dominance) is reported a ratio 7:2:1 between the treated women [35].
Adenomyosis is characterized by the development of ectopic endometrial glands 
and a stroma in the myometrium, at a depth > 2.5 mm from the endometrial-
myometrial separation surface and moreover by hypertrophy or hyperplasia of 
the smooth muscles of the myometrium [36–39]. An older description is given 
by Rokintasky 1860 adenoid cystosarcoma of the uterus and for the first time by 
Frankl 1925 the term of adenomyosis of the uterus. [36–39]. Clinical diagnosis of 
adenomyosis is only hypothetical, histological examination poses diagnosis of the 
disease after hysterectomy. [36–39]. It is diffuse (adenomyosis) or focal (adeno-
myoma), asymmetrically affects the uterine wall of premenopausal women (usually 
the posterior) and often coexists with myomas [36–39]. The disease is common 
(5% - 70% in the surgical series, using strict criteria 10% - 18%), progressing and 
manifested with non-specific symptoms, which are similar to the symptoms caused 
by myomas (bleeding - anemia, pain, dysmenorrhea, dyspareunia, pelvic load (bulk 
symptoms) - sensitive uterus or a combination of the above), so it is difficult to 
diagnose only by clinical criteria [36–39]. An incidence of 10% -30% is described, 
in hysterectomy preparations it was found in a percentage of 10% - 18%. 80% of 
women with adenomyosis have another uterine condition like pelvic endometriosis 
and endometrial polyps (2% - 20%) endometrial hyperplasia, adenocarcinoma 
[36–39]. In 35% of women with adenomyosis do not show any symptoms and 
the diagnosis of the disease is random [38–41]. The pathogenesis of adenomyosis 
remains unknown. Etiology: According to various studies the endometrial glands 
of the disease express more in immunochemical examinations the ratio of HCG/
LH receptors found in endometrial cancers and trophoblastic disease, compared 
to natural [36–39]. Other theories of pathogenesis include elevated estrogen 
levels, endometrial injuries in surgeries such as scraping, fibromyectomy, cesarean 
section, and residual of Muller Duct. Adenomyosis occurs mainly in multiparas 
with an incidence of 5–70%. Symptoms of adenomyosis (menorrhagia (50%), 
dysmenorrhea (30%), uterine bleeding (20%), dyspareunia (sporadic additional 
symptom) [38–41]. The clinical diagnosis of adenomyosis is only hypothetical and 
only histological diagnosis makes the diagnosis of the disease after hysterectomy. 
Preoperative transvaginal ultrasonography (TVUS) and magnetic resonance (MRI) 
are useful diagnostic examinations Main diagnostic TVUS criteria are as following: 
asymmetrical uterine enlargement, subendometrial halo thickening, indistinct 
endometrial myometrial border, myometrium is thickened ventrally and associated 
to heterogeneous echotexture. MRI is another recommend imaging examination 
preprocedural of UAE with higher specificity compared to TVUS approximately 
(86–96%)and excellent to recognize fibroids,adenomyomas if the myometrial 
thickness is increased or the myometrium occur anatomical area changes In focal 
adenomyosis occurs low signal intensity within the myometrium, while in diffuse 
adenomyosis appear the junctional zone diffuse thickening also with low signal 
intensity in T2 weighted MRI The treatment options are: Drug treatment (usually 
ineffective), Presence of estrogen receptors in fibroids promote the increase in 
fibroid size. Progesteroids such as medroxyprogesterone acetate, norethindrone in 
GnRH-suppressed patients may increase in size. Stimulation of fibroid enlargement 
is a complex process involving the interaction of estrogen-progestogens in combi-
nation with local growth factors [38–41]. Antiprogesteroids such as mifepristone 
RU-486 reduce fibroid size. Invasive treatment of fibroids: myomectomy (open 
- intra-abdominal, laparoscopic, hysteroscopic), hysterectomy, myolysis - catalysis 
cryocatalysis, thermal catalysis by microwave or radio frequency (RF-ablation), 
ultrasound focus catalysis (FUS) and laser photocatalysis] and uterine artery 
percutaneous embolization (UAE) [38–42].
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5. Clinical symptoms of fibroids
The majority of 60–70% are asymptomatic. The clinical recognized significantly 
underestimates the true occurrence due to the fact that the routine ultrasound 
screening in not obligatory indicated [43–46].
Approximately 62% of women with symptomatic fibroids visit the gyne-
cologists due to multiple symptoms depending on their anatomical location, 
(subserosal, intramural, submucosal or intracavity) size number and associated 
degenerative morphological changes [43–46]. The referred symptoms are as fol-
lowing: abnormal vaginal bleeding (most common), anemia, pelvic mass, frequent 
urination, possible incontinence constipation tenesmus rectal pressure, pelvic 
pain and infertility[43–46]. Pregnancy related fibroid behavior: growth which is 
reported controversy concerning to increasing or remain the same the uterus size, 
degeneration, pain, spontaneous abortions, obstetric complication (premature 
labor in 15%, intrauterine restriction in 10% and malpresentation in 20%) .[43–46]. 
The pregnancy in coesting of fibroids depending on their anatomical location 
and the distance to placental site. Other rare associations are as following: Ascites 
development due the transudation of fluid after torsion and obstruction of vessels 
in floating fibroids, Polycythemia secondary detected, familial syndromes with 
renal cell carcinoma, intravenous leiomatosis and benign matastasizing uterine 
fibroids [43–46].
The most common symptom in the majority of cases in clinical practice is the 
abnormal vaginal bleeding. This symptom in association with myomas occurs either 
as menorrhagia or hypermenorrhea, while metrorrrhagia is not typical for fibroids 
and need more investigation to rule out malignancies. The exact mechanism of 
abnormal bleeding from fibroids is not yet well known. Fibroids alter the nature 
of uterine muscle contractions and prevent the uterus from controlling the degree 
and intensity of bleeding during menstruation. The submucosal fibroids due to 
total or partial protrusion in uterus cavity led most likely to menorrhagia while the 
intramural myomas have obstructive effect on uterine vessels and subsequent led to 
endometrial vessels ectasia with profuse menstrual bleeding [43–46].
Hypermenorrhea occur most likely in endometritis in association to submucous 
myomas. The palpation of myomas based on enlarged irregular uterine contour 
can be useful to clinically diagnosis of fibroids and the findings described as uterus 
size like in pregnancy [43–48]. If the uterus size is more than 12–20 week can be 
palpated on abdominal examination. In cases of increased size of uterus arise 
pelvic pressure on adjacent organs like urinary tract, rectosigmoid with frequent 
urination, ureteral obstruction tenesmus due to incarceration of enlarged uterus in 
Douglas pouch and dysmenorrhea [43–48].
The incidence of malignant mutation in sarcomas is reported to be 0.1–0.29% 
of diagnosed fibroids [43, 49, 50]. Leiomyosarcoma is an independent malignant 
tumor in the absolutely majority and arises de novo, however recently published 
studies reveal that in very rare cases is possible in fibroids with chromosome dele-
tions to develop in leiomyosarcoma most common in the 5th–6th decade of life. 
Γλωσσική επιμέλεια.
It is characterized by extensive abnormal bleeding and a rapid increase in 
uterine size in postmenopausal patients [43, 49, 50]. The main microscopic fea-
tures which are significant predictors of leiomyosarcoma clinical course included: 
coagualtive tumor cell necrosis, degenerating hyperchromatic, pleomorphic nuclei, 
cytologic atypia, mitotic index MI (MI denotes definite mitotic figures (mf) per 
10 high power field (hpf) MI ≥ 5mf/10hpf, differentiation. In case of fibroids, the 
MI < 5mf/10hpf no atypia and necrosis and in the subgroup of leiomyosarcoma or 
smooth muscle of uncertain malignant potential (STUMP) [43, 49, 50]. In STUMP 
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tumors the main diagnostic criterion associated to prognosticate biologic behavior 
is the MI < 5mf/10hpf but is presence of moderate to severe atypia without necrosis 
[43, 49, 50]. The least subgroup of tumors is accompanied by lymph nodes in the 
lung or other sites with histopathological occurrence similar to the original tumor 
approximately 15 years after hysterectomy. Immunostaining for expression of cell 
cycle regulatory proteins like Ki-67,cyclins E,A,cdks (cdk2,cdc2), p16, progesterone 
receptors, p53 Her-2/neu based on significant elevated levels in leiomyosarcomas 
can be useful in discriminating and identifying STUMP tumors, leiomyosarcoma 
and fibroids [43, 49, 50].
6. Treatment options
The uterine fibroids is the most common uterine pathology with a prevalence 
more than 25% of all reproductive years and approximately 1.6 million women in 
United States diagnosed with uterus myomatosus. Asymptomatic fibroids could 
be found incidentally on pelvic imaging and management therapeutical strategy 
depending on their causing clinical symptoms [51]. If cases which are asymptomatic 
need not any treatment and after menopause due to their regression expectant 
management is the recommended therapy option. In symptomatic fibroids based on 
the most common symptoms, heavy menstrual bleeding and painful menstruation 
is very useful. Fibroid classification system based on the fact that the above men-
tioned symptoms caused by fibroids which distort the uterine cavity [49].
Fibroid classification system is referred as following:
Type 0 completely intracavity fibroids.
Type1 ≥ 50% in the cavity intramural.
Type 2 < 50% in the cavity intramural.
Type 3 intramural but approach endometrium.
Type 4 intramural.
Type 5 subserosal but at least 50% intramural.
Type 6 subserosal but less than 50% intramural.
Type 7 subserosal pedunculated.
Type 8 cervical [51].
According to Donnez [52, 53] staging, submucosal fibroids are classified as 
following:
Grade I Fibroids with the largest diameter in the endometrial cavity.
Grade II Fibromyomas with the largest diameter in the myometrium.
Grade III Appearance of multiple fibroids>2.
7. Medical treatment
Medical therapies based on therapeutical manipulating the fibroid hormonal 
environment. Steroid hormones, especially estrogen and progesterone are associ-
ated to fibroids behavior, proved by clinical molecular biological pharmacological 
models and play an important role to their medical treatment. The combination of 
estrogen progestin or progestin alone is the first line medical therapy for uterine 
fibroids.
GnRH (gonadotropin releasing hormone)-agonists led to down regulation of 
GnRH receptors at level of pituitary after initially increase the release of gonado-
tropins flare effect of heavy vaginal bleeding, reduce the FSH (follicle stimulating 
hormone) LH (luteinizing hormone) and ovarian steroid hormone and produce 
a hypoestrogenic menopause state [52–56]. Subsequent results amenorrhea and 
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reduction of the size of fibroids pronounced within three months after beginning of 
treatment [54–58]. The reduction can reach 40–50% of the tumor in 3 months but is 
reversible after stopping treatment. This effect is more pronounced in submucosal 
fibroids due to a higher number of estrogen and progesterone receptors.
GnRH antagonists often used to treat myomas before surgical procedure, 
block pituitary receptors and led immediately to declination of FSH, LH levels 
and fibroid, uterus volume reduction within 3 weeks of therapy beginning. Their 
directly promptly block gonadotropin effect has rapid clinical character and is 
associated to initial flare effect. They are currently indicated only for ovulation 
induction [54–58].
The presence of aromatase in fibroids and additional to ovarian estrogen activ-
ity, interleukin 1βc AMP analoque, prostaglandin E2 led to estrogen production in 
fibroids cells [54–58]. Fibroids express aromatase higher levels compared to sur-
rounding intact myometrium. In these cells occur significant conversion of andros-
tendione to estrone and subsequent to estradiol which has full biologic activity and 
act positively to significant stimulation of proliferation of fibroids cells [54–58].
Aromatase inhibitors inhibit ovarian and peripheral estrogen production due 
to cellular proliferation inhibition, androstendione inhibition and reduce estradiol 
levels after 24 hours of treatment. SERMs (selective estrogen receptor modulator) 
are nonsteroidal agents who bind estrogen receptor and based on target tissue show 
estrogen agonist or antagonist effect [51, 59, 60]. While the SERM Tamoxifen has 
agonist effect in endometrium, Raloxifen exhibit no agonist activity and decrease 
the fibroid size. Antiprogesterone agents act at the level of progesterone receptors 
(PR-A PR-B), which are abundant in the fibroid. It is reported that progesterone 
induce proliferation, up regulate growth factors, antiapoptotic proteins like EGF in 
fibroid cells [51, 59, 60]. Mifepristone is the most studied antagonist of progester-
one and due to high progesterone affinity led to amenorrhea, reduction of fibroid 
size and improvement the clinical symptoms [51, 59, 60]. The administration of 
ulipristal acetate, who is a selective progesterone receptor modulator, has proved 
successful effects on therapy of fibroids with clinical symptoms reduction of their 
size and endometrium cystic glandular changes. Danazol (19a nortestosterone 
derivate) inhibits pituarity gonadotropin secretion, led to ovarian steroid produc-
tion and suppression of endometrial growth after 6 months treatment [51, 59, 60]. 
The use of progestin containing intrauterine contraceptive device (LNG -IUDs) as 
local therapy for menorrhagia and symptomatic uterine fibroids has been studied 
and confirmed a significant reduction in bleeding and fibroid size. However uterus 
myomatosus with a distorted uterine cavity or a submucosal fibroid is a contarindi-
cation for LNG –IUD [51, 59, 60].
8. Surgical treatment
Although the traditional treatment for uterine fibroids remains the hyster-
ectomy either abdominal or vaginal classical, total laparoscopic assisted vaginal 
hysterectomy, robotic assisted laparoscopic hysterectomy as the predominant 
surgical procedure, however is preferred only in women who have completed their 
family planning [61–65].
In late reproductive age and premenopausal period available therapeutic options 
to preserve the uterus allow possible an attempt at conception and are surgical or 
conservative options. Over the past decade, the hysterectomy rate has decreased 
while alternative therapy options for symptomatic fibroids have been increased. The 
surgical procedures include myomectomy, abdominal myomectomy, laparoscopic 
myomectomy, laparoscopic thermal ablation, percutaneous ablative methods, 
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hysteroscopic myomectomy, myolysis, laparoscopic morcellation and finally uterine 
artery ligation and occlusion performed either as surgical ligation during laparos-
copy [61–65]. (παρακάτω θα μπορούσε να μπεί παράγραφος για τους κινδύνους της σε 
περίπτωση STUMP tu).
In cases of laparoscopic morcellation is of great importance to exclude based 
on evaluations criteria like presence of coagulations necrosis, no significant atypia 
and mitotic index ≤10 STUMP tu due to unknown malignant potential behavior. 
Minimally invasive therapies non-surgical procedures are as following: Magnetic 
resonance guided focused ultrasound ablation (MRgFUS) and UAE. MRgFUS 
based on ultrasound energy through the abdominal layers without requirement 
of incisions under real time MRI monitoring to reduce fibroid size [66]. Γλωσσική 
επιμέλεια UAE blocks selective the uterine artery blood flow led to shrink of fibroids 
[67]. The goal of this review was to report our 12 years of experience from the 
impact of UAE on ovarian reserve (OR) (which refer to number and quality of the 
follicles left in the ovaries) of normal menstruating premenopausal women and to 
estimate the degree of pain and inflammation caused by UAE in our patients based 
on AMH levels and inflammatory parameters (CRP, temperature, white blood cells) 
respectively.
9. UAE uterine artery embolization as treatment option
UAE to treatment of fibroids as alternative to surgical procedure was reported 
for first time by Ravina in 1995 [67]. This is not only treatment option for fibroids 
but used successfully also in refractory postpartum bleeding, or after gynecologic 
surgery, abnormal malignancy suspicious vaginal bleeding or in cases with uterine 
arteriovenous malformation. Although several reports confirm satisfactory results 
of treatment of symptomatic fibroids without necessity of surgical procedure based 
on the optimal cooperation between gynecologist and interventional radiologist, 
however the absolutely majority is retrospective and exist no prospective random-
ized trials to prove the effectiveness of this procedure compared to other therapy 
options [67–70]. The UAEs were performed in the Department of Radiology by an 
experienced interventional radiologist.
9.1 Preprocedureal management
All study participants were normal menstruating premenopausal women aged 
between of 38–50 years old (42.6 ± 7 years on average), had attended the depart-
ment of obstetrics and gynecology of our University hospital complaining of serious 
symptoms of uterine fibroids (menorrhea, anemia, pelvic pain, bulky symptoms, 
pressure effects) underwent UAE for uterus fibromyomas and/or adenomyosis 
(pure or mix type). The enrolled premenopausal women diagnosed with and normal 
ovarian reserve as defined by AMH and FSH measurements (serum FSH concentra-
tion > 10 IU/L (on day 3 of menstrual cycle), serum AMH (2–8 pg./l). In all patients 
were available cervical pap smear test and previously performed fractional curettage. 
Exclusions criteria: Women with pelvic infection, pregnant (or willing to be preg-
nant) women, cases suspicious of any pelvic malignancy, postmenopausal women, 
women with resistant clotting disorders or severe allergy to contrast media, ovula-
tory problems, previous ovarian surgery, PCOS (polycystic ovarian syndrome) or 
coagulopathy, immunocompromised, previous pelvic irradiation or women who had 
been offered hormonal therapy for fibroids with GnRh agonists, were excluded. All 
patients underwent MR Imaging on a 1.5 Tesla (Multiva, Koninklijke Philips N.V.) or 
an 1 Tesla equipment (GE Healthcare, Milwaukee, USA) up to 60 days before UAE, 
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using phased-array pelvic coils (Figure 1a-f). MR imaging included at least sagittal, 
coronal and transverse T2-weighted images, T2*-weighted images, T2-weighted fat 
saturated images, Diffusion-weighted images, T1-weighted images, and sagittal, 
coronal and transverse fat saturated T1-weighted images pre and post contrast. 
AMH, FSH, TSH, LH, fT 4 E, PROG, PROL, TESTOST and DHEAS were measured 
on day 3 of the menstrual cycle before UAE. C reactive protein (CRP) and white 
blood cell count lab exams were carried out prior to and after UAE. Two patients 
that had undergone fibromyectomy and with fibromyoma recurrence were included. 
Preoperative imaging management enhances the ability to diagnosis and to identify 
pathology induced anatomic changes and is crucial in optimizing information to 
treatment.
Transvaginal ultrasonography (TVUS) has an efficacy of 65–99% and consists 
the gold standard for imaging of the woman’s pelvis. MRI is crucial in the diagnosis. 
Differential diagnosis with MRI has a sensitivity of 88% - 93% and a specificity of 
66% - 91%. MRI examination is important to rule out malignancy in the uterus, 
eg sarcoma and to identify nondegenerated fibroids. Degenarated fibroids occur 
as hyalinized fibroids, cystic changes as hypertense, myxoid degeneration as high 
signal intensity, necrotizing has components of necrotizing or coagulative necrosis.
9.2 UAE
All patients had signed a written consent before the UAE. The UAE procedures 
were performed in the hybrid angiography suite of Radiology Department using a 
biplane angiography system (Philips Allura Xper Cath/angio system, Koninklijke 
Philips N.V.).
Bilateral UAE was performed, under local anesthesia, i.v. antibiotic prophylaxis, 
and sedation when required. In all cases a bladder catheter has been placed. The 
Figure 1. 
Description of UAE procedure course.
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procedure included a single percutaneous puncture of the right common femoral 
artery, selective crossover contralateral and unilateral advance of a 4-French flush 
angiographic catheter (Simmons 1 or Cobra 1) to both uterine arteries. When the 
catheter bypassed the arteries for the vagina and cervix, administration of the 
embolic particles started. In the most of the cases a 2.7-Frence or 2.8-Frence micro-
catheter (Progreat, Terumo Europe, Leuven, Belgium) has then been positioned 
away from the cervicovaginal branches (Figure 2a-f).
Special radiation protection care was taken, using fluoroscopic guidance of the 
catheterizations, fluoroscopy time reduction to the minimal possible and, mostly, 
fluoroscopic imaging of contrast angiography opacifications.
Fibroid ischemia was achieved by using of spherical, tightly calibrated, bio-
compatible, non-resorbable, hydrogel coated microspheres, 700 μm and 900 μm in 
diameter (Embozene, CeloNova BioSciences Inc./Boston Scientific, San Antonio, 
USA). The angiographic embolization endpoint was defined as complete stasis of 
contrast agent in the ascending segment of the uterine artery during selective digi-
tal subtraction angiography at the end of the embolization procedure. Adenomyosis 
patients were embolized with the use of 500 μm and/or 700 μm Embozene micro-
spheres. Criterion for the particle administration stop in adenomyosis cases was the 
fluoroscopic finding of “almost complete stasis”.
9.3 Postprocedureal management
Regarding pain treatment, post-intervention 50 mg of pethidine was intramus-
cular administered, and after 4 hours the dosage was repeated by intramuscular 
injection in the first 24 hours. 100 mg tramadol was taken every 6 hours and anti-
inflammatory tablets were taken every 12 hours for a week. Pain assessment results 
were determined based on a visual analogue scale (0 min-10max). After daily stay 
Figure 2. 
MRI imaging of fibroid course pre- and post embolization.
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at the hospital, patients were discharged and administered broad spectrum anti-
biotics for one week. Clinical, laboratory and imaging follow up examinations by 
trans–vaginal ultrasonography and MRI scans of the patients were performed at the 
1rst, 3rd, 6th and 12th month after the procedure (Figure 1e-f).
Main outcome measures were menstruation, hormonal status and presence of 
menopausal symptoms. Hormonal status and ovarian reserve were evaluated by 
means of AMH and FSH serum levels on 1st, 3rd, 6th and 12th month after UAE. 
Subsequently, FSH and LH levels began to decrease and reached the base line values 
on the 12th month after UAE (Figure 3) [71]. The AMH levels showed a decrease 
on the 1st month, reaching the minimum values on the 3rd month and retaining 
the base line values on the 3rd month in contrary to the other examined hormones. 
No Case of amenorrhea was noted in women ≤45 years old, while 0.6% of women 
>45 years old experienced amenorrhea only the first 3 months after UAE 
(Figure 4) [71] According to our findings, a leukocytosis value of up to 16,000 Κ/
μl and an increase in CRP level of up to 8 mg/dl, are not alarming [70]. In our study 
were included only premenopausal women and especially women who completed 
their family planning. However, reported two unplanned pregnancy cases, which 
they have decided to terminate the pregnancy. We have no noticed no case for 
emergency hysterectomy. In Table 1 are summarized the complications in our par-
ticipants and according to international literature with the maximally respectively 
referred complications rate. The first column of the table refers to our results in the 
time from 2008 to 2020 while in the second column are shown the respective values 
of the examinated parameters in average concerning to international literature 
[72–76].
The course of myoma size according to a follow up for a period of 1 year post 
UAE was mean reduction 75% of fibroid volume compared to fibroid size before 
beginning of treatment. The percentage of technical success of the performed UAEs 
was estimated at 100% and the MRI examinations revealed that the uterine volume 
continues to shrink over follow up time. In no case was noticed continuity of wors-
ening preprocedure symptoms, permanent amenorrhea, necessity of subsequent 
hysterectomy or minimal shrinkage of fibroid size after 6 months postprocedural. 
The positive results expressed as clinical included: Reduce of bleeding and pressure 
symptoms and as imaging reduction in uterine size and fibroids. According to our 
Figure 3. 
Hormonal changes (FSH,LH) during the follow up period (Tsikouras et al. [71]).
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findings after UAE the fibroids shrank by 60–70% and the size of the uterus by 
50–60%. In particular, mild symptoms of metabolic syndrome in four cases were 
observed. Over time, shrinkage increases. The reduction in symptoms is expected to 
be close to 98%.
Specifically, menstruation improved in 95–100% of cases, while symptoms 
(flatulence, pelvic pressure and frequency) are reduced to 91–100% depending on 
how the result is calculated. High satisfaction rates for women. The recurrence of 
fibroids reaches 4%, but is thought to be due to an increase in the size of old incom-
plete embolized myomas and adenomyosis. The main cause of failure was not the 
initial size of the fibroids, but their failure shrank below 30% of the original size. In 
three cases it was mandatory to repeat the procedure of UAE due to the anatomical 
location of the fibroids, intra-ligamentally.
Figure 4. 
Hormonal changes (AMH) during the follow up period (Tsikouras et al. [71]).
Our results
Range (min-max)
International literature results
Range (min-max)
Transient amenorrhea
< 45 years old 0.2–0.5% 1–2%
> 45 years old 1.5% 2–4%
Permanent amenorrhea 0
< 45 years old 0 2–3%
> 45 years old 0 5–6%
Fibroma protrusion 0.3%
Aseptic endometritis 0.1–0.2% 2%
Septic endometritis 0 1.2%
Uterine necrosis 0 <1%
Unsuccessful UAE 0 <1%
Table 1. 
UAE complications: our results and various published reports.
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10. Discussion
UAE is a minimally invasive procedure which improves symptoms by inter-
rupting the blood flow uterine vessel branches to fibroids after bilateral (from 
right and left) hyper-selective catheterization of the myometric feeder arteries and 
embossing of pistons induceing irreversible ischemic damage and degeneration/
shrinkage in the fibroids. [65, 75–80] According to bibliography, therapy success 
rate during menorrhagia, was is 80–100% and at? pressure phenomena 60–100%. 
A decrease in fibroid size by 40–70% was noted in the first 6 months, followed by 
50–80% in the months that ensued [67, 77–82]. There are various reports regard-
ing uterus size course [67, 77–82]. Some authors mention uterus size as criteria, 
whilst others use both fibroids and uterus size as successful therapy assessment 
criteria. Inflammation appearance rate is 1–2% based on tissue reactions due to post 
interventional ischemia is an interaction between cells and cytokine and should be 
diagnosed at an early stage so that sepsis, hysterectomy and death can be avoided 
[81–84]. There have been reports of 100.000 successful UAEs in total so far [84–87].
Patients should be notified in detail and contact their doctor. Fundamental is the 
co-operation between gynecologist and interventional radiologist before, during 
and after UAE. In general, complications include either catheterization or the 
effects of uterine ischemia that can cause fibrotic necrosis, pain and septic imaging. 
The ovaries may be affected. The reported deaths following UAE are extremely rare 
(approximately 1: 1600) and are mainly related to pulmonary embolism, which may 
be due to the effect of necrotic tissue on activation of the coagulation mechanism 
and on inflammation. The complications of catheterization are rare (<1%), such 
as hematoma, allergy to contrast media and pseudo-aneurysm or vascular separa-
tion [75, 76, 87–90]. Elimination of uterine fibroids occurs in 5% of cases and can 
cause inflammation requiring scanning or hysterectomy. The necrotic tissue, if not 
removed in time, can become infected and the condition becomes severe. Cases 
with submucosal fibroids should be treated hysteroscopically [75, 76, 87–90]. 
Ischemia may cause endometritis, pelvic inflammation and pyometra with poor 
outcome if hysterectomy does not occur. According to the literature, menorrhagia  
is successfully treated in 91–100% of cases, while symptoms such as flatulence, 
pressure on organs of the pelvis and loss of urine are reduced to 92–100%  
[67, 75, 76, 87–90]. Uterine size does not appear to be a determinant, as remission of 
symptoms is also common in patients with a uterus greater than 24 weeks gestation. 
These results are also confirmed by studies of the last four years, which show that 
patients are 98–1000% satisfied [67, 75, 76, 87–90]. UAEs also have a beneficial 
effect in cases of adenomyosis, although there is not much experience. In a series of 
28 patients with genuine adenomyosis an improvement of 95.3% was recorded  
[67, 75, 76, 87–90]. Although there are no long-term data, follow-up of up to 
72 months shows postembolization syndrome include: pain and cramps (eliminated 
in the first hours after procedure with good/systemic analgesic treatment), nausea 
and fever (controlled with appropriate medications), aseptic or (rarely) septic 
inflammation (in a few patients, total 4 in our study controlled with anti-inflam-
matory/antibiotics) for 3–6 months) or (rare) menopause after UAE (small number 
of patients, almost always aged>45 years) [67, 75, 76, 87–90]. In these cases were 
diagnosed large fibroids and the reported complications affect range according to 
published literature 2–15% needed readmission for monitoring of symptoms. The 
necessity of hysterectomy after UAE approximately reported in 1% of cases. In our 
study participants reintervention was necessary only in 4 cases due the anatomical 
fibroid positions. According to international literature reintervention’s rate is by 
9% at 1 year and 28% at 5 years [67, 75, 76, 87–90]. Pregnancies in the majority after 
the UAE reported and delivered at term without serious complications, however 
Fibroids
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the cesarean section rate is high approximately 33–50% [67, 75, 76, 87–91]. Based 
on current medical knowledge concerning genetics and molecular biology of 
uterine fibroids will be the basis of development microarray analysis to investigate 
genes, which involved in fibroid formation and provide more specific and effective 
minimally preventive fibroid therapies to early intervention and improve the life 
impact of women.
11. Conclusion
UAE is a safe and effective treatment option for uterine fibroids with inter-
national recognition, however further multicentric studies required to provide 
clinical data and participate in randomized control trial to compare with the known 
surgical procedures.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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